Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02700659 · ClinicalTrials.gov registry record
The Cxbladder Monitoring Study
A clinical trial of Urothelial Carcinoma, sponsored by Pacific Edge Limited.
- Completed
- Registry status
- 803
- Enrollment target
- 11
- Study locations
NCT02700659 is a study of Urothelial Carcinoma that has completed, run by Pacific Edge Limited. The registered enrollment target is 803 participants, above the 230-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (249% higher). The trial reports 11 study locations across 8 states.
The verdict
NCT02700659, a study of Urothelial Carcinoma, has completed, sponsored by Pacific Edge Limited.
- COMPLETED
- Registry status
- 803 participants
- Enrollment target
- 11
- Study locations
Study Summary
The aim of this trial is to determine the performance characteristics of the Cxbladder test for the detection of recurrent urothelial carcinoma (UC) in patients with a recent history of urinary tract UC, who have been treated according to standard practice and are undergoing routine investigative cystoscopy. The gold standard for determination of clinical truth is cystoscopy, plus any follow up investigations relating to the current visit.
Conditions Studied
Interventions
- OTHER Cxbladder
Study Locations (11)
New York
- Premier Medical Group of the Hudson Valley - Kingston
- Weill Cornell Medical College, Department of Urology - New York
- Premier Medical Group of the Hudson Valley - New York
- Premier Medical Group of the Hudson Valley - Newburgh
Alabama
- Urology Centers of Alabama - Homewood
Connecticut
- Urology Center of Grove Hill, One Lake Street - New Britain
Florida
- Florida Urology Associates - Orlando
Idaho
- Idaho Urologic Institute - Meridian
New Jersey
- Delaware Valley Urology, LLC - New Jersey
Pennsylvania
- Penn State Hershey Medical Center and College of Medicine - Hershey
Texas
- UT Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 803 participants |
| Start Date | 2013-02-04 |
| Est. Completion | 2016-09-23 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02700659
The ClinicalTrials.gov registry entry for NCT02700659 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 803 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 230-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (249% higher). The listed sponsor is Pacific Edge Limited, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Urothelial Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Cxbladder is the first listed.
NCT02700659 reports 11 study locations spanning 8 distinct geographic areas - top geographies include New York, Alabama, Connecticut.
Frequently Asked Questions
What is clinical trial NCT02700659 about?
NCT02700659 is a clinical study titled "The Cxbladder Monitoring Study". The aim of this trial is to determine the performance characteristics of the Cxbladder test for the detection of recurrent urothelial carcinoma (UC) in patients with a recent history of urinary tract UC, who have been treated according to standard practice and are undergoing routine investigative cy...
What is the current status of trial NCT02700659?
This trial is currently completed. The enrollment target is 803 participants. The study started on 2013-02-04. Estimated completion is 2016-09-23.
What conditions does trial NCT02700659 study?
This clinical trial studies the following conditions: Urothelial Carcinoma.
What interventions are being tested in trial NCT02700659?
The interventions under investigation include: Cxbladder (OTHER).
Who is sponsoring clinical trial NCT02700659?
This trial is sponsored by Pacific Edge Limited, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02700659 being conducted?
This trial has 11 study locations across Alabama, Connecticut, Florida, Idaho, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urothelial Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Detection and Risk Stratification in Veterans Presenting With Microscopic Hematuria
RECRUITING
-
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
RECRUITING · Phase 3
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
RECRUITING · Phase 2
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.